Summary:
This study is a Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects with Irritable Bowel Syndrome Experiencing Abdominal Pain
Qualified Participants Must:
• Be male or female
•
18 to 70 years old
•
Clinical diagnosis of Irritable Bowel Syndrome
Qualified Participants May Receive:
- Compensation for participation and travel
- Free consultation at our Hyde Park office
- Travel provided from our Hyde Park office to our Stony Island office